# A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

> **NCT05214339** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma
- Hepatocellular Carcinoma by BCLC Stage

## Interventions

- **DRUG:** Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab

## Key facts

- **NCT ID:** NCT05214339
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-16
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05214339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05214339, "A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05214339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*